Efficacy of Neoadjuvant Chemotherapy in Distal Pancreatectomy with En Bloc Celiac Axis Resection (DP-CAR) for Locally Advanced Pancreatic Cancer
- 78 Downloads
Distal pancreatectomy with en bloc celiac axis resection (DP-CAR) is an extended surgical procedure for patients with locally advanced cancer of the pancreatic body and tail. Recently, the usability of neoadjuvant chemotherapy (NAC) in pancreatic cancer was reported. The purpose of this study was to clarify the impact of NAC on surgical outcomes and prognosis in DP-CAR patients.
This study retrospectively reviewed 20 consecutive patients who underwent DP-CAR at a single institution.
Eleven of 20 patients (55.0%) received NAC. Their first regimens were gemcitabine (GEM) plus nab-PTX (n = 7, 63.6%), GEM plus S-1 (n = 3, 27.3%), and GEM (n = 1, 9.1%). Although two patients converted to a second regimen, none abandoned NAC due to adverse effects or could not undergo a planned procedure for disease progression. There were no significant differences in intraoperative variables, morbidity, including pancreatic fistula and delayed gastric emptying, and mortality between patients with and without NAC; however, patients with NAC had a significantly lower proportion of arterial invasion (p = 0.025), lymphatic invasion (p < 0.0001), and vascular invasion (p = 0.035). There were no significant differences in the induction rate of adjuvant chemotherapy (p = 0.201). The recurrence-free survival and overall survival rates in patients with NAC were significantly higher than in patients without NAC (p = 0.041 and p = 0.018, respectively).
DP-CAR following NAC was associated with a preferable prognosis and had no negative effect on surgical outcomes. Therefore, NAC in DP-CAR patients might be a beneficial and safe therapeutic strategy.
KeywordsNeoadjuvant chemotherapy DP-CAR Appleby Pancreatic cancer
Borderline resectable disease
Common hepatic artery
Delayed gastric emptying
Distal pancreatectomy with en bloc celiac axis resection
Gemcitabine plus S-1
Left gastric artery
Mean survival time
The National Comprehensive Cancer Network
Pancreatic ductal adenocarcinoma
Superior mesenteric artery
Union for International Cancer Control
We thank H. Nikki March, PhD, from Edanz Group (www.edanzediting.com/ac) for editing a draft of this manuscript.
S.Y. participated in the study conception and design, analysis, and drafting of the article.
K.F. participated in the study conception and design and critical revision of the manuscript.
S.I., Y.F., K.S, K.I., S.I., N.H., T.I., and T.Y. participated in the acquisition of data, analysis, and interpretation of data.
M.M participated in the critical revision of the manuscript.
Compliance with Ethical Standards
All patients provided written informed consent, and the study protocol was approved by the Ethical Committee of Oita Red Cross Hospital (IRB No. 189).
Conflict of Interest
The authors declare that they have no conflict of interest.
- 2.Wakao F, Higashi T, Katanoda K et al. Cancer statistics in Japan 2017. Tokyo: Foundation for Promotion of Cancer Research (FPCR), 2018.Google Scholar
- 4.NCCN Clinical Practice Guidelines in Oncology Pancreatic Adenocarcinoma, version 3. www.nccn.org. 2017.
- 20.Dhir M, Zenati MS, Hamad A et al. FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel for Neoadjuvant Treatment of Resectable and Borderline Resectable Pancreatic Head Adenocarcinoma. Ann Surg Oncol 2018; 25: 1896–1903.Google Scholar